These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23824381)
21. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434 [TBL] [Abstract][Full Text] [Related]
22. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b. Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536 [TBL] [Abstract][Full Text] [Related]
23. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Manns MP; Markova AA; Calle Serrano B; Cornberg M Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J; J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320 [TBL] [Abstract][Full Text] [Related]
25. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602 [TBL] [Abstract][Full Text] [Related]
26. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529 [TBL] [Abstract][Full Text] [Related]
27. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646 [TBL] [Abstract][Full Text] [Related]
28. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407 [TBL] [Abstract][Full Text] [Related]
29. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591 [TBL] [Abstract][Full Text] [Related]
30. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P; J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789 [TBL] [Abstract][Full Text] [Related]
31. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin. Miyasaka A; Kumagai I; Abe K; Suzuki K Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909 [TBL] [Abstract][Full Text] [Related]
32. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P; Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484 [TBL] [Abstract][Full Text] [Related]
34. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188 [TBL] [Abstract][Full Text] [Related]
35. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1. Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M J Med Virol; 2010 Sep; 82(9):1537-44. PubMed ID: 20648607 [TBL] [Abstract][Full Text] [Related]
36. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654 [TBL] [Abstract][Full Text] [Related]
38. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin. Selvapatt N; Habibi MS; Brown A J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248 [TBL] [Abstract][Full Text] [Related]
39. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448 [TBL] [Abstract][Full Text] [Related]
40. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]